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Abstract 
Background  
We recently assigned a new fibrinolytic function to cell-derived microparticles in vitro. 
The relevance of this novel property of microparticles to the in vivo situation was 
explored in these studies. 
Design and Methods  
Circulating microparticles were isolated from plasma of thrombotic thrombocytopenic 
purpura or cardiovascular disease patients and from healthy subjects. Microparticles 
were also obtained from purified human blood cell subpopulations. Identification of 
plasminogen activators on microparticles was performed by flow cytometry and ELISA, 
their capacity to generate plasmin quantified with a chromogenic assay and their 
fibrinolytic activity by zymography. 
Results 
Circulating microparticles isolated from patients generate a range of plasmin activity at 
their surface. This property was related to a variable content in uPA and/or tPA. Using 
distinct microparticle subpopulations, we demonstrate that plasmin is generated on 
endothelial and leukocyte microparticles, but is absent on microparticles from platelet 
or erythrocyte origin. Leukocyte-derived microparticles bear uPA and its receptor 
uPAR whereas endothelial microparticles carry tPA and tPA/inhibitor complexes.  
Conclusions  
Endothelial and leukocyte microparticles, bearing respectively tPA or uPA, support a 
part of the fibrinolytic activity in the circulation that is modulated in pathological 
settings. This blood-borne fibrinolytic activity conveyed by microparticles provides a 
more comprehensive view on the role of microparticles in the hemostatic equilibrium. 
 
Key words: fibrinolytic microparticles, plasmin(ogen), uPA, tPA 
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Introduction 
 
 Microparticles (MPs) are small vesicles resulting from membrane blebbing of 
most activated or apoptotic cells. MPs derived from blood and vascular cells are 
detected in the circulation and over the past decade have been accepted as diagnostic 
and prognostic biomarkers in cardiovascular and inflammatory diseases, and in 
cancer.(1) Accumulating evidence indicates that beyond their clinical relevance as a 
biomarker, MPs also convey various bioactive effectors from the parental cell. 
Previous in vitro and in vivo studies indicate that MPs propagate a spectrum of 
biological activities and are involved in many different processes, such as activation of 
coagulation, inflammation, vascular remodeling and angiogenesis.(2-6) They bear 
tissue factor-dependent procoagulant activity and regulate procoagulant pathways in 
monocytes.(7) They also carry cytokines important for inflammation(8, 9) and 
participate in endothelial dysfunction by decreasing the production of nitric oxide.(4) 
Besides, it has been shown that endothelial MPs carry on their surface matrix 
metalloproteinase activity, suggesting their participation in extracellular matrix 
degradation, vascular remodeling and angiogenesis.(3)  
We previously assigned a hitherto unreported fibrinolytic function to MPs(10) 
and more recently, we demonstrated that they participate in a new fibrinolytic crosstalk 
mechanism.(11) In these in vitro studies performed with MPs derived from the human 
microvascular endothelial cell line, HMEC-1, we demonstrated that these endothelial 
MPs constitute a catalytic surface for efficient activation of plasminogen by the 
urokinase-type plasminogen activator (uPA) anchored to its receptor uPAR.(10) 
Interestingly, these MPs may also activate plasminogen bound to fibrin, extracellular 
matrix proteins or platelets.(11) The possibility that circulating MPs also serve as a 
template for plasmin formation and fibrinolytic activity in vivo and their cellular origin 
remains unsolved questions that are the object of the present study. We demonstrate 
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here that blood-borne MPs are a source of fibrinolysis that is modulated in different 
pathological situations. This fibrinolytic activity is selectively and specifically generated 
by uPA on leukocyte MPs and by tPA on endothelial MPs. This novel mechanism of 
plasmin formation in vivo may counterbalance the effect of procoagulant MPs by 
contributing to lysis of fibrin clots.   
 
Design and Methods 
 
Isolation of microparticles from human plasma  
Platelet-poor plasma was separated (1500g, 15 minutes) from blood collected into 
0.119 M sodium citrate from healthy volunteers (n=36) and from patients with systemic 
lupus erythematosus (n=22) according to the American College of Rheumatology 
criteria(12) or with atherosclerotic complications (n=16) collected during a previous 
study(13). Citrated plasma was also obtained by plasmapheresis from patients 
suffering from acute thrombotic thrombocytopenic purpura (TTP, n=10). Informed 
consent was obtained from all patients according to the Declaration of Helsinki.   
MPs were isolated by sequential centrifugation of platelet-poor plasma, first at 
12000g for 2 minutes to remove residual platelets. The platelet-free plasma was then 
centrifuged at 20000g for 90 minutes at 4°C. Centrifugation at 100000g, reported in 
some studies, was avoided to prevent concomitant sedimentation of exosomes, a 
different type of membrane vesicles.(14, 15) Pelleted MPs were washed twice (20000g 
for 90 minutes at 4°C) and re-suspended in phosphate buffer saline. In some 
experiments, circulating MPs were depleted in erythrocyte and platelet microparticles 
by magnetic immuno-separation using beads coated with CD41 and CD235a 
antibodies. Depletion in MPs (superior to 90%) was checked by flow cytometry 
(Supplemental data I). Control experiments were performed in parallel using beads 
coated with irrelevant antibodies. 
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Generation of microparticles from blood cells  
To investigate which subtype of circulating MPs may support plasminogen 
activation activity, MPs were generated in vitro from purified blood cell types. To that 
aim, whole blood from healthy volunteers or patients, who had not taken anti-platelet 
medication for at least 2 weeks, was collected into 0.119 sodium citrated tubes.  
Human platelets prepared as described(16) were incubated with 1 NIH U/mL of 
thrombin and/or 1 µ M of ionophore A23187 (Sigma, Saint Louis, MO), and/or 10 
µg/mL of collagen (Stago, Asnière, France), for 15 minutes at 37°C without stirring. 
Platelets were subsequently pelleted by centrifugation first at 1500g for 15 minutes. 
Residual platelets were discarded by centrifugation at 12000g for 2 minutes and 
microparticles were then isolated from the supernatant and washed as described 
above. Purity superior to 95 % was checked by flow cytometry. 
Erythrocyte MPs were generated as previously described by Salzer et al. with 
minor modifications.(17) Erythrocytes pelleted at 200g for 10 minutes and 
subsequently washed in sodium chloride 0.9%, were suspended in 9 volumes of PBS 
containing 1 mM CaCl2 and 5 µM of A23187 and incubated at 37°C for 30 minutes. 
Erythrocytes were subsequently separated by centrifugation at 12000g for 2 minutes, 
and MPs isolated and washed as described above. Purity superior to 95 % was 
checked by flow cytometry. 
Leukocyte MPs were prepared as previously described with minor 
modifications.(18) Peripheral blood mononuclear cells were isolated from buffy coats 
by FicollTM (Lymphocytes separation medium 1077). Monocytes were isolated by 
CD14+ immuno-magnetic separation on MS columns (Miltenyi Biotec, Bergish 
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Gladbach, Germany). Purity superior to 95 % was checked by flow cytometry. 
Monocytes were stimulated by LPS (1µg/ml) overnight. Vesiculation was evaluated by 
FCM using Annexin A5-FITC/CD11b. Neutrophils were purified from buffy coats and 
were stimulated by N-formylmethionyl-leucyl-phenylalanine (1 µM) during 2 hours at 
37ºC. Lymphocytes were purified from blood mononuclear cells and were stimulated 
by platelet-activating factor 500 nM/ phorbol 12-myristate 13-acetate 50 nM during 2 
hours at 37ºC. MPs were isolated and washed as described above.   
 
Generation and harvesting of microparticles from endothelial cells 
 Several subtypes of human endothelial cells originating from distinct vascular 
beds were purchased from Clonetics (Grand Island, NY) and cultured into 0.2 % 
gelatin coated flasks in EGM2-MV medium: renal artery endothelial cells were used at 
passage 8, coronary artery endothelial cells at passage 7 and both dermal human 
microvascular vein endothelial cells and human pulmonary artery endothelial cells at 
passage 6. Endothelial MPs were purified from culture medium conditioned by sub-
confluent endothelial cells stimulated or not with 10 ng/mL TNF-a (PeproTech Inc, 
Rocky Hill, NJ, USA) for 24 hours, as previously described with some 
modifications.(19) Culture supernatants were centrifuged at 300g for 5 min and 2500g 
for 10 min to remove detached cells and debris. MPs were isolated as described 
above, were washed twice and re-suspended in HEPES buffer.  
 
Characterization of microparticles by flow cytometry and ELISA 
MPs suspension aliquots of 10 µ L, 1/10 diluted, were labeled using fluorescein 
isothiocyanate (FITC)-conjugated annexin A5 (Abcys, Paris, France) or specific 
monoclonal antibodies. Phycoerythrin (PE)-labeled anti-CD41, FITC anti-CD31, PE 
anti-CD11b and PE anti-CD235a were from Beckman Coulter (Marseille, France). 
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Flow cytometry analysis (Supplemental data II) was performed on Cytomics FC500® 
instrument (Beckman Coulter,Miami, FL, USA). MPs were analyzed as previously 
described. (20, 21) 
The presence of uPA, uPAR and tPA was evaluated by flow cytometry using FITC-
labeled antibodies on MPs gated on CD146-PE (endothelial MPs), CD59-PE 
(endothelial MPs, erythrocyte MPs and leukocyte MPs) or CD41-PE (platelet MPs) 
positivity. Matched antibodies for protein concentration and fluorescence/protein ratio 
were used as control.  
Pelleted MPs were lysed in 100 mM Tris-HCl buffer pH 8.1, containing 0.5% Triton 
X-100 and supplemented with a complete protease inhibitors mixture (Roche 
Diagnostic GmbH, Mannheim, Germany). Concentrations of uPA and uPAR were 
assayed by ELISA (894 and 893 IMUBIND® ELISA kits, American Diagnostica, 
Greenwich, GB) according to the manufacturer’s instruction. The results were 
expressed as ng of protein per 106 MPs. The tPA and plasminogen activator inhibitor 
type-1 (PAI-1) content were measured by ELISA (Asserachrom® tPA and 
Asserachrom® PAI-1, Diagnostica Stago, Asnière, France). Results were expressed 
as ng of protein per 106 MPs. 
 
Determination of plasminogen activators, plasminogen activation and 
fibrinolytic activity on microparticles 
The presence and identity of plasminogen activators and its inhibitors borne by 
MPs were analyzed by direct and reverse fibrin autography following SDS-PAGE 
performed as described previously.(22) Briefly, MPs were lysed in 100 mM Tris-HCl 
buffer, pH 8.1, containing 1% Triton X-100. MPs lysates (10 µL from 2.105 MPs) and 
reference proteins (10 µ L of tPA 5 nM, uPA 1 nM and plasmin 500 nM) were 
electrophoresed in a 7.5% polyacrylamide gel under non-reducing conditions. SDS 
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was then exchanged with 2.5% Triton X-100. After washing-off Triton X-100 excess 
with distilled water, the gel was carefully overlaid on a 1% agarose gel containing 1 
mg/mL of bovine fibrinogen, 100 nM plasminogen and 0.2 NIH U/mL of bovine 
thrombin. For reverse fibrin zymography, the fibrin gel was supplemented with 0.05 
i.u./mL of urokinase. Zymograms were allowed to develop at 37°C during 24 hours and 
photographed at regular intervals using dark-ground illumination. Active proteins in MP 
lysates were identified by reference to the migration of known markers (uPA, tPA, 
plasmin). When required the fibrin-agarose indicator gel was supplemented with 
antibodies (10 µg/mL) directed against specific plasminogen activators.  
The capacity of MPs to activate plasminogen was determined by incubating a fixed 
concentration of plasminogen (1 µM) with the MPs in the presence of a chromogenic 
substrate selective for plasmin (CBS 0065, 0.75 mM final concentration), as described 
previously.(10) Plasmin formed from plasminogen bound at the surface of MPs 
cleaves the chromogenic substrate and the released p-nitroaniline is detected by 
measuring A405nm as a function of time. Results are expressed in A405nmx10-3/min. 
When indicated, the following inhibitors were pre-incubated with the MPs: 10 µg/mL 
goat anti-human tPA (Biopool, Uppsala, Sweden), 20 µg/mL mouse anti-human uPA 
(American Diagnostica 3940), and respective irrelevant control IgGs (Biocytex, 
Marseille, France); amiloride and ε -aminocaproic acid (ε-ACA; Sigma-Aldrich) were 
used respectively at 100 µM and 0.05 M, final concentrations.   
To scale the degree of plasmin formation by MPs, a standard curve prepared with 
reference MPs (200 000 per 50 µL) bearing known molar amounts of either uPA or tPA 
(THP1- or CHO-derived MPs, respectively) was used (see Supplemental data III for 
preparation of reference MPs).  
The fibrinolytic activity of MP-free plasma from patients and controls was estimated 
by measuring the amount of plasmin formed on a fibrin surface in contact with the 
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plasma euglobulin fraction in the presence of CBS 0065 (0.75 mM final 
concentration).(23) 
 
Statistical analysis 
Statistical analysis was performed with KaleidaGraph software (Synergy Software, 
Reading, PA, USA). Significant differences were determined using non-parametric 
Mann-Whitney test. A p value less than 0.05 was considered significant. 
 
Results  
In vivo evidence of blood-borne fibrinolytic activity supported by microparticles: 
identification of plasminogen activators 
To investigate the possibility that blood-borne MPs may be involved in plasmin 
generation under conditions fashioned in vivo, we studied MPs from healthy controls 
and patients with pathological states reported to be associated with increased MP 
concentration, namely atherosclerotic vascular disease (n =16) and systemic lupus 
erythematosus (n = 22). MPs were isolated by centrifugation of platelet-free plasma at 
20000g for 90 min. Therefore, all experiments presented in this paper excluded the 
presence of exosomes and concern exclusively MPs as indicated by nanoparticle 
tracking analysis (Supplemental data IV, figure S6). As illustrated in figure 1, it was 
possible to detect varying levels of plasminogen activator activity on MPs in both 
controls and patients. Interestingly, the plasminogen activator activity of MPs was 
significantly higher in the two groups of patients compared to healthy controls (median, 
25-75 percentile: 1.2, 0.6-1.93 mOD/min and 0.87, 0.61-1.59 mOD/min versus 0.5, 
0.4-0.6 mOD/min, p<0.003 and p<0.007, respectively). However, around 50% of 
patients had a plasminogen activator activity similar to healthy controls. 
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The nature of plasminogen activators involved in the fibrinolytic activity was 
analyzed using samples obtained by plasmapheresis from patients with acute TTP, a 
pathological situation featuring increased vesiculation.(24, 25) Plasmapheresis has the 
advantage over classical blood sampling, of providing sufficient amounts of plasma for 
MP isolation and extensive characterization. All isolated MP samples (n=10) generate 
plasmin activity upon incubation with 1 µM plasminogen. Figure 2A shows plasmin 
generation (0.7-5.9 mOD/min) in TTP samples (2.105 MPs per well) that display a 
variable content in plasminogen activator activity (control in the absence of MPs: 0.015 
mOD/min). The inhibition of plasminogen binding and plasmin generation by ε-ACA 
was consistent with a lysine-dependent mechanism for plasminogen binding and 
activation at the surface of MPs (Figure 2B). The plasminogen activator activity in 
distinct samples (Figure 2C upper panel) was identified as uPA (TTP 6) or tPA (TTP 7) 
in fibrin-agarose gels, as indicated by the position of their fibrinolytic bands relative to 
known markers. For instance, the single fibrinolytic band apparent in sample TTP 6 
and the corresponding uPA standard were absent in a fibrin-agarose gel containing 
anti-uPA antibodies (Figure 2C, lower panel). This antibody also inhibited plasmin 
formation by MPs from TTP 4 in a chromogenic assay (Figure 2B). The MP sample 
TTP 7 in figure 2C produced fibrinolytic bands of increased intensity corresponding to 
the position of uPA, tPA and tPA in complex with its inhibitor. The uPA fibrinolytic band 
did not appear in the presence of anti-uPA antibodies whereas tPA and its complexes 
retained their activity (Figure 2C, lower panel). In two additional TTP samples it was 
possible to quantify the molar activity of plasminogen activators on 2.105 MPs per 50 
µL (tPA: 1.93 and 0.84 pM; uPA 1.5 and 0.83 pM). For this purpose we used reference 
MPs bearing known molar concentrations of either tPA or uPA and amiloride to resolve 
tPA activity (Supplemental data III). Free tPA and tPA in complex with its inhibitor were 
also identified in SLE samples (Supplemental data V, figure S7). These results provide 
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the first evidence that human circulating MPs convey plasminogen activators and 
activate membrane-bound plasminogen. These ex vivo data suggest that blood-borne 
MPs may generate and disseminate plasmin activity in vivo.  
 
The fibrinolytic activity in circulating blood is borne by leukocyte- and 
endothelial-derived microparticles 
To further explore the fibrinolytic activity of MPs, we determined the cellular 
origin of MPs bearing plasminogen activator activity. We first performed experiments 
using specific antibodies coated on magnetic beads, allowing to deplete samples in 
platelet and erythrocyte MPs, representing the major subpopulation of circulating MPs. 
Less than 10% residual platelet MPs and erythrocyte MPs were detected in depleted 
samples (Figures 3A, 3B). The predominant subpopulations of endothelial MPs and 
leukocyte MPs in the depleted sample generated a significant increase in plasmin 
formation as compared to the non-depleted sample (Figure 3C). These data suggest 
(1) that endothelial MPs and leukocyte MPs represent the genuine support of 
plasminogen activator activity and (2) that platelet or erythrocyte MPs do not contribute 
to the fibrinolytic activity of MPs isolated from circulating blood. Of note, platelets and 
platelet MPs bear active PAI-1 (Figure 3D). Thus, the unexpected increase in plasmin 
formation observed in the depleted samples was probably related to the absence of 
platelet MPs bearing active PAI-1. 
To define which plasminogen activators are specifically borne by MPs of 
endothelial and leukocyte origin, we studied the fibrinolytic activity of isolated MPs 
(2.105 per well) derived from distinct purified blood cell subpopulations and from 
primary human endothelial cells. 
Endothelial-derived microparticles. Plasmin generation was detected on endothelial 
MPs with variations according to their anatomical origin (Figure 4A). Extremes high 
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and low fibrinolytic activities were displayed by endothelial MPs of renal artery (1.2±0.2 
mOD/min) and dermal microvascular origin (0.03±0.01 mOD/min), respectively. By 
zymography, two fibrinolytic bands resistant to anti-uPA antibodies were observed in 
endothelial MP lysates (Figure 4B). The lower band corresponded to the migration of 
purified tPA whereas the top band, of higher molecular weight, corresponded to the 
migration of tPA in complex with its inhibitor (Cs in Figure 4B), in agreement with a 
previous report.(22) Consistent with this observation, significant levels of PAI-1 antigen 
were detected in lysates of endothelial MPs with a specific ELISA (Figure 4C). The 
presence of tPA was further confirmed by ELISA (Figure 4D) and by flow cytometry 
(Supplemental data II, figure S3), whereas uPA activity and antigen were 
undetectable. The molarity of active tPA borne by endothelial MPs was determined by 
reference to standard MPs bearing known molar amounts of tPA (Table 1). 
Leukocyte-derived microparticles. Plasminogen activator activity was also detected on 
leukocyte MPs of monocyte, lymphocyte and neutrophil origin (Figure 4A). The 
presence of such activity on leukocyte MPs was further confirmed by a lytic band on 
zymography corresponding to the position of uPA (Figure 4B) that was absent in the 
presence of antibodies to uPA (not shown). Flow cytometry (Supplemental data II, 
figure S3) and ELISA (Figure 4D) allowed detection of uPA and its receptor uPAR on 
the surface of leukocyte MPs. In a parallel experiment, tPA antigen was undetectable 
on leukocyte MPs (Supplemental data II, figure S3). The molarity of uPA borne by 
leukocyte MPs was calculated using reference standard MPs bearing known molar 
amounts of uPA (Table 2).  
Platelet- and erythrocyte-derived microparticles. Both platelet MPs and erythrocyte 
MPs (up to 5.106 MPs per well) failed to generated plasmin (Figure 4A) and fibrinolytic 
bands (Figure 4B). Accordingly, depletion of erythrocyte and platelet MPs did not 
decrease the fibrinolytic activity of MPs isolated from plasma (Figure 3C). Similar 
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negative results on plasminogen activator activity were obtained when platelet MPs 
were generated using different platelet agonist combinations (collagen, thrombin and 
A23187; not shown). Flow cytometry experiments failed also to detect uPA or tPA 
antigens on platelet or erythrocyte MPs (Supplemental data II, figure S3).  
Collectively, these results indicate that active plasminogen activators expressed by 
endothelial cells and leukocytes, tPA and uPA respectively, are conveyed in circulating 
blood by endothelial and leukocyte MPs. 
 
Discussion 
 Using the human microvascular endothelial cell line HMEC-1,(26) we previously 
reported that endothelial MPs convey a fibrinolytic activity in vitro and participate in a 
fibrinolytic crosstalk.(10, 11) However, the relevance of this model to fibrinolysis in vivo 
and whether MPs derived from all circulating cell types support plasminogen activation 
remained unsolved questions that were addressed in the present studies. First, we 
provide the proof of concept that MPs produced in vivo support fibrinolysis as indicated 
by the formation of active plasmin on MPs isolated from blood of healthy subjects and 
patients with vascular diseases. Second, we show that specific plasminogen activators 
on endothelial and leukocyte MPs generate this fibrinolytic activity, whereas 
erythrocyte and platelet vesicles do not have this property. Third, the plasminogen 
activators were identified as u-PAR-bound uPA, on leukocyte MPs, and tPA on 
endothelial MPs. Therefore, the present study originally contributes to identify new 
partners of blood-borne fibrinolytic activity. 
 We also provide evidence that MPs with fibrinolytic activity are found at very low 
concentration in healthy subjects whereas various levels of plasmin formation were 
found in different pathological situations (atherosclerosis, systemic lupus 
erythematosus and TTP). This varying level of ex vivo fibrinolytic activity reflects 
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different amounts of active plasminogen activator borne by MPs whereas the 
plasminogen activator activity of MP-free plasma was negligible as published 
previously.(23) The significance of these findings with regard to the clinical status 
remains to be established in future studies. Notwithstanding, we have revealed the 
existence of a MP-dependent profibrinolytic compensatory mechanism that may 
counterbalance the procoagulant phenotype and reduce the thrombotic risk in these 
patients.(24, 27-29) These interesting features put forward the basis for a potential 
new biomarker.  
 To identify MPs that bear these plasminogen activators, we studied MPs 
subpopulations released by primary endothelial cells in culture or by platelets, red cells 
and leukocytes isolated from circulating human blood that were properly stimulated. 
We provide here the first demonstration that plasminogen activators are borne in a 
selective manner by a minor fraction of MPs circulating in human blood: endothelial 
MPs carry tPA and leukocyte MPs carry uPA/uPAR. This selectivity contrast with the 
well-described procoagulant potential common to all MPs.(30) Interestingly, we found 
various levels of fibrinolytic MPs in differents pathological situations (arteriosclerosis, 
systemic lupus erythematosus, TTP) that have been reported to be associated with 
increased levels of leukocyte and endothelial MPs.(13, 19, 27, 28, 31-34) This 
fibrinolytic activity may reflect pathophysiological leuko-endothelial activation 
associated with inflammation that helps to identify patients with a higher individual 
vascular risk in these clinical situations. Of note, leukocyte MPs and endothelial MPs 
are among the least accessible circulating subsets by current methodologies, such as 
flow cytometry, because of their low proportion, size distribution and limited specific 
markers. Thus, the measurement of this circulating activity brings innovative 
information to these MP subsets, as compared to their counting alone.   
DOI: 10.3324/haematol.2012.066167
 16 
 The study of MP samples from patients suffering of TTP demonstrates that 
plasmin may be generated either by uPA or tPA. By combining a set of tests 
(chromogenic, zymography, ELISA) and flow cytometry, we demonstrate that this 
activity was exclusive on MP subsets derived from either leukocytes (expressing uPA) 
or endothelial cells (expressing tPA). These distinctive characteristics may 
advantageously be used to identify the origin of the plasmin generation capacity of 
circulating MPs in patients. The presence of uPA on MPs derived from the human 
microvascular endothelial cell line HMEC-1 described in our previous report(10) was 
due to the atypical synthesis of this plasminogen activator by the modified cell line 
HMEC-1, that was used as a model to generate MPs after TNFα stimulation.  
 In contrast to uPA-bearing MPs derived from circulating leukocytes and tPA-
bearing MPs derived from human primary endothelial cells, we did not detect plasmin 
generation on erythrocyte and platelet MPs. Accordingly, plasminogen activators have 
not been described on red blood cells and their expression by human platelets is not 
clearly demonstrated, except for the ectopic production of uPA in the platelet Quebec 
syndrome.(35) It is therefore possible that platelet MPs may, in some cases, develop 
plasminogen activator activity. Indeed, since platelets bind plasminogen,(36-38) 
platelet MPs may be a source of substrate for enhanced fibrinolysis by scuPA(39) via 
a fibrinolytic cross-talk mechanism we demonstrated recently.(11) However, active 
PAI-1/vitronectin complexes present in platelets(40) and active PAI-1 detected in 
platelet MPs as shown in this study, may modulate this fibrinolytic activity. Given that 
both platelet and erythrocyte MP subpopulations account for the bulk of circulating 
MPs,(13) it was relevant to demonstrate the effect of their depletion from the pool of 
MPs isolated from plasma. The unexpected increased fibrinolytic activity generated by 
the depleted samples may reflect the absence of platelet MP bearing active PAI-1. 
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 Thus, we have identified MPs of endothelial and leukocyte origin as the main 
sources of the plasmin generation capacity on MPs in human plasma. However, in 
pathological settings, it remains possible that MPs from other origins may carry 
proteolytic activity in plasma. For instance, tumor MPs were proved to circulate and 
have been associated to thrombosis due to the tissue factor they convey.(41, 42) 
Facing this property, MPs from tumor cell lines and from ascites of cancer origin were 
found to bear vesicle-associated proteolytic activity represented by matrix 
metalloproteinases 2 and 9 and plasminogen activators.(43-47) The discovery of 
fibrinolytic MPs that circulate in human plasma raises the possibility to detect such 
activity in some cancer patients with potential role in diagnostic relevance or 
prognostic value in metastatic evolution. 
Beyond fibrinolysis, plasmin formation by microparticles bearing the uPA/uPAR system 
may participate, in concert with matrix metalloproteinases, in other proteolytic 
functions.(48) Thus, the proteolytic activity of uPA-bearing MPs may be of relevance in 
cell migration, angiogenesis and outside-in signal transduction. Indeed, we have 
previously shown that tube formation was stimulated at low concentrations of MPs, 
(10) an effect that was related to crosstalk activation of plasminogen present in the 
Matrigel.(49) This proangiogenic effect is consistent with plasmin associated 
proteolytic activity that favors cell migration via extracellular matrix processing. The 
role of MP-bound plasmin in pathological settings involving inflammation, 
atherosclerosis and angiogenesis remains to be investigated. The high concentration 
of MPs reported in atherosclerotic plaques suggests that plasmin generation on MP 
could participate in the modulation of cell apoptosis/angiogenesis balance influencing 
plaque vulnerability.   
 In summary, our study indicates (1) that circulating human MPs display a range 
of plasmin generation in various pathological conditions, (2) that this activity is 
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specifically generated by tPA on endothelial MPs and by uPA on leukocyte MPs, and 
(3) that these MPs support blood fibrinolytic activity. We provide the first evidence that 
surface plasminogen activation is a functional feature of plasma MPs that significantly 
differ between healthy subjects and pathological samples. Altogether, these results 
suggest that the presence of profibrinolytic MPs during clot formation anticipates their 
potential for clot lysis.  
The existence of profibrinolytic MPs in the circulation raises the question about the 
physiological relevance of this activity. Our data suggest that pro-fibrinolytic MPs may 
compensate the effect of procoagulant MPs. Further studies will be necessary to 
correlate procoagulation versus fibrinolytic effects of MPs with the clinical status of 
patients. Microparticle blood-borne fibrinolytic activity not only provides a more 
comprehensive view on their role in the hemostatic equilibrium but also puts forward 
the basis for a potential new biomarker. 
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Table 1. tPA activity on endothelial cell-derived microparticles. 
200 000 MPs per 50µL tPA (pM) 
Renal artery endothelial cells  7.6 ± 1.0 
Coronary artery endothelial cells 3.9 ± 0.1 
Human microvascular endothelial cells 1.2 ± 0.2 
 
 
 
 
Table 2. uPA activity on leukocyte-derived microparticles. 
200 000 MPs per 50µL uPA (pM) 
Neutrophils 0.5 ± 0.07 
Lymphocytes 0.2 ± 0.06 
Monocytes 0.4 ± 0.03 
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Figure 1. Plasmin generated by circulating microparticles from patients with 
cardiovascular disease (CVD), systemic lupus erythematosus (SLE) and healthy 
controls (HC). 
Microparticles (2.105 per well) were isolated as indicated in Methods and then 
incubated with plasminogen (1µM) in the presence of a plasmin-selective chromogenic 
substrate (CBS 0065, 0.75mM). Dots represent the amount of plasmin formed 
(mOD/min). Results represent the median (25-75 percentile) of a duplicate experiment. 
The median for each category is represented by the dotted lines.  CVD 1.2 (0.6-1.93) 
mOD/min and   SLE 0.87 (0.61-1.59) mOD/min versus  HC 0.5 (0.4-0.6) mOD/min, 
*p<0.01. 
 
 
Figure 2. Plasmin generation and fibrinolytic activity of microparticles isolated from 
patients with thrombotic thrombocytopenic purpura (TTP). 
A. Plasmin generation by 10 MP TTP samples. Experiments were performed as 
indicated in figure 1. Results in mOD/min (mean±SD).   
B. Effect of inhibitors (100mM ε-aminocaproic acid, ε -ACA and 20µg/mL anti-uPA 
antibody, a-uPA) and IgG, a control immunoglobulin, on plasmin generation by TTP 4 
MPs. Experiments performed as indicated in figure 1. Results in mOD/min (mean±SD). 
C. Fibrin-zymography analysis of TTP MPs. Proteins in MP lysates were separated by 
SDS-PAGE and their fibrinolytic activity revealed on fibrin-agarose gels. Reference 
standards are: purified tPA, plasmin (Pn) and uPA. The fibrinolytic activity was tested 
in the absence (-, upper panel) or presence (+, lower panel) of 10 µ g/mL of a 
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polyclonal antibody against uPA. The high molecular weight fibrinolytic band observed 
in the purified tPA standard lane correspond to tPA dimers.(50)  
 
 
Figure 3. Platelet- and erythrocyte-derived microparticles do not exhibit fibrinolytic 
activity. 
A. Immuno-phenotyping monitoring of platelet MPs (Annexin A5-FITC+/CD41-PE+) 
and erythrocyte MPs (Annexin A5-FITC+/CD235a-PE+) before and after immuno-
magnetic depletion (representative experiment). Left panels show MP content after 
non-specific immuno-magnetic separation (IMS control). Right panels show MP 
content after anti-CD41/CD235a IMS.  
B. Efficiency of the IMS depletion in MPs of platelet and erythrocyte origin (right panel, 
n=3, 11.9%+/-1.43%, p<0.05) expressed as a percentage of the non-depleted samples 
(left panel).  
C. Plasmin generation by MPs in depleted and non-depleted samples. Left bar shows 
activity of the non-depleted sample compared to the activity, right bar, of the sample 
depleted of erythrocyte and platelet MPs (145%+/-11%, p<0.05). An equal volume of 
25µL of depleted and non-depleted MP samples was tested.  
D. Reverse fibrin-zymography analysis of platelet MPs. Proteins in platelet MPs 
lysates (20 µg) and non-activated platelets (80 µg) were separated by SDS-PAGE and 
their plasminogen activator inhibitory activity was revealed on a fibrin-agarose gel 
containing urokinase (0.025 I.U./mL). The reference standard is purified recombinant 
PAI-1 (80 ng).  Representative samples are shown. 
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Figure 4. Plasminogen activators and fibrinolytic activity of human circulating blood 
cell- and primary endothelial cell-derived microparticles.  
MPs derived from circulating human platelets, leukocytes and erythrocytes, and from 
primary cultures of human endothelial cells were prepared and isolated as indicated in 
Methods. Endothelial MPs were obtained from primary cultures of coronary artery 
(CA), pulmonary artery (PA), renal artery (RA) and dermal microvascular (DMV) 
endothelial cells. Circulating blood cell-derived MPs were obtained from isolated 
polymorphonuclear cells (PMN), monocytes (MC), lymphocytes (LC), red cells (RC) 
and platelets (PLA).  
A. Plasmin generation by MPs (2.105 per well) was tested as indicated in figure 1. Bars 
represent the amount of plasmin formed (mOD/min). Results are the mean ± SD of 
duplicate experiments (n=3). 
B. Fibrin-zymography analysis of endothelial and circulating MPs. Zymography was 
performed as indicated in Methods. Reference standards are purified tPA, plasmin 
(Pn), uPA and tPA in complex with PAI-1 (Cs). Representative samples are shown. 
C. Concentration of uPAR and tPA determined by ELISA in cell-derived MP lysates 
(106 endothelial MPs per well). Results are the mean ± SD of duplicate experiments. 
D. Concentration of PAI-1 as determined by ELISA in cell-derived MP lysates (106 
endothelial MPs per well). Results are the mean ± SD of duplicate experiments. 
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I. Immuno-phenotyping monitoring of platelet- (PMP), Erythrocyte- (EryMP) and 
leukocyte-derived (LMP) microparticles immuno-magnetic depletion (representative 
experiment).  
 
 
 
 
 
 
Figure S1. Immuno-phenotyping monitoring of PMP and EryMP immuno-magnetic 
depletion.  
A. Untreated samples. B. Non-specific immuno-magnetic depletion using beads coated with 
irrelevant antibody. C. PMP and EryMP immuno-magnetic depletion. MP subpopulations 
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were defined as PMP (AnnV+/CD41+) and EryMP (AnnV+/CD235a+). LMP 
(AnnV+CD15+) was used as control. D. Percentage of post immuno-magnetic separation 
(IMS) residual MP showing a selective immunomagnetic depletion of PMP and EryMP (n=3). 
 
II. Measurement of plasminogen activators at the microparticle surface.   
 
Figure S2. Example of flow cytometry protocol for the measurement of plasminogen 
activators at the microparticle surface.   
A. Calibration protocol with Megamix beads. Megamix (BioCytex, Marseille, France) are 
fluorescent size-calibrated beads allowing standardization of the MP window of analysis 
(Robert et al., J Thromb Haemost 2009). Briefly, Megamix beads have a specific 2:1 ratio 
between 0.5 µm and 0.9 µm beads. First, beads were detected using a FL1 threshold (0.5 µm 
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beads in D box, 0.9 µm beads in E box). Then, threshold was switched to FS. The lower limit 
of the standardized MP gate was defined by settings such as the 0.5/0.9 µm beads ratio was 1 
(about 50/50%) and the upper limit with a 0.9 µm beads autogate. B. Representative density 
plots of t-PA detection on HCAEC derived-MP (Human Coronary Arterial Endothelial Cells). 
HCAEC-MP were identified as CD146+ events in MP gate. Fluorescence and concentration 
matched irrelevant antibody (IgG-FITC; left density plot) was used as control of tPA-FITC 
antibody (right density plot).  
Figure S3. Detection of uPAR, uPA and tPA at the surface of endothelial and circulating 
MPs by flow cytometry. Graphs represent overlays of representative fluorescence histograms 
obtained with isotype controls (grey) and tPA, uPA or uPAR specific antibodies (black) on 
annexin A5+ gated events. MFI: mean fluorescence intensity. Endothelial cell-derived 
microparticles were obtained from primary cultures of coronary artery (CA), pulmonary 
artery (PA), renal artery (RA) and dermal microvascular (DMV) endothelial cells. Circulating 
blood cell-derived MPs were obtained from isolated polymorphonuclear cells (PMN), 
monocytes (MC), lymphocytes (LC), red cells (RC) and platelets (PLA). MIF: mean 
fluorescence intensity. 
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III. Preparation of reference microparticles bearing plasminogen activators 
A standard curve prepared with reference microparticles (200 000 MPs per 50 µL) carrying a 
fixed known amount of either tPA (CHO-derived MPs) or uPA (THP1-derived MPs) was 
used to scale the degree of plasmin formation on respectively endothelial or leukocyte MPs.  
First, reference CHO-derived MPs or THP1-derived MPs were prepared by incubation with a 
saturating amount of respectively tPA or uPA. The molarity of activator on these MP 
suspensions was then determined by reference to a binding isotherm (figure S1) relating 
plasmin formation versus varying amounts of plasminogen activator bound to the 
corresponding cells (50 µL per well). The MPs suspensions were tested at 200 000 MPs per 
well. Parameters for each binding isotherm were calculated using the Langmuir equation 
(Adamson A.W. 1990 in Physical chemistry of surfaces, pp695-606) and are indicated at the 
figure bottom. The tPA molarity, 4.5 nM, of the CHO-derived MPs reference preparation was 
calculated from the binding isotherm. The uPA molarity, 7.17 nM, of THP1-derived MPs 
reference preparation was calculated from the binding isotherm.  
 
 
 
 
 
 
 
 
 
Figure S4. Binding isotherms of of uPA on THP-1 cells (black line) and tPA on CHO 
cells (blue line). The initial linear part of the isotherm was used to calculate the molarity of 
either tPA carry by CHO MPs or uPA carry by THP-1 MPs, both tested at 200 000 MPs per 
50 µL. 
           uPA 
Kd = 0.11 ± 0.01nM  
Vmax = 19.5 ± 1.5 mOD/min 
 
 
             tPA 
Kd = 0.08 ± 0.04 nM 
Vmax = 6.1 ± 1.2 mOD/min 
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Second, standard curves of plasmin generation by tPA-bearing or uPA-bearing MPs (50 µL) 
were prepared by plotting the amount of plasmin generated versus varying concentrations of 
the activator on MPs. The amount of tPA carry by endothelial-derived MPs and uPA carry by 
leukocyte-derived MPs were then determined using the equation of this curve. 
 
                     y = 63.7 x                   y = 621 x 
 
 
 
 
 
 
Figure S5. Standard curves of plasmin generation by uPA- or tPA-bearing MPs. 
 
IV. Nanoparticle tracking analysis 
 
 
 
 
 
Figure S6. Nanoparticle tracking analysis (Nanosight LM10). Microparticles were isolated 
by centrifugation (20 000g, 90min) from a pool of plasmas (platelet-free plasma 1 500g, 
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15min, then 12 000g, 2min). The graph shows the size distribution of microparticles in the 
sample. Less than 2% of events were under 100nm size. 
 
V. Identification of plasminogen activators in microparticles of systemic lupus 
erythematosus patients. 
 
 
 
 
 
 
 
 
 
Figure S7. Fibrin-agarose zymography of microparticles isolated from patients with 
systemic lupus erythematosus. Fibrin-zymography analyses of TTP MPs. Proteins in MP 
lysates were separated by SDS-PAGE and their fibrinolytic activity revealed on fibrin-agarose 
gels. Reference standards are: purified tPA and uPA. Zymography was performed as indicated 
in Methods. The lysis zone in the tested samples corresponds to tPA in complex with PAI-1 
(upper band) and to tPA (lower band, arrow).  
tPA   uPA    SLE1    SLE2   SLE3   SLE4   SLE5    SLE6 
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